AtriCure to Participate in the Stifel 2024 Healthcare Conference

ATRC 11.07.2024

Full Press ReleaseSEC FilingsOur ATRC Tweets

About Gravity Analytica

Recent News

  • 02.12.2025 - Q4 2024 AtriCure, Inc. Earnings Conference Call
  • 01.22.2025 - AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results
  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
  • 12.12.2024 - 4 Statement of changes in beneficial ownership of securities
PDF Version

MASON, Ohio--(BUSINESS WIRE)--Nov. 7, 2024--AtriCure, Inc.(Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Stifel 2024 Healthcare Conference.

AtriCure’s management is scheduled to participate in a fireside chat onMonday, November 18, 2024, at9:10 am Eastern Standard Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website athttps://ir.atricure.com

AboutAtriCure

AtriCure, Inc.provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe useAtriCuretechnologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure’s Isolator®SynergyTM Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip®Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AFTM Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE®probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visitAtriCure.comor follow us on X (formerly Twitter)@AtriCure.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241107221308/en/

Angie WirickAtriCure, Inc.Chief Financial Officer(513) 755-5334awirick@atricure.com

Marissa BychGilmartin GroupInvestor Relationsmarissa@gilmartinir.com

Source:AtriCure, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com